Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480471 | 0.87 | KEAP1 (0.47) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4482823 | 0.85 | CHRM2 (0.45) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4495026 | 0.81 | ALDH1A1 (0.45) | CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL4486313 | 0.81 | ALDH1A1 (0.45) | CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL4470397 | 0.80 | CHRM2 (0.41) | CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL4490304 | 0.80 | CHRM2 (0.41) | CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL4483807 | 0.80 | CHRM3 (0.53) | CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL4483970 | 0.80 | CHRM3 (0.53) | CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL4479620 | 0.79 | MEN1 (0.46) | ALDH1A1 | |
| SCHEMBL4486748 | 0.79 | KEAP1 (0.43) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176856-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-07-09 | — | — | US | claimed |
| EP-1796667-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | claimed |
| WO-2006035282-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | claimed |
| US-20090176856-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-07-09 | — | — | US | disclosed |
| EP-1796667-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035282-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176856-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM1 5/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.